PDSB News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PD

Mkt Cap

$82.3M

Volume

6.71M

Next Earnings

November 12th

Loading chart

PD

PDSBPDS Biotechnology Corporation Common Stock

PDSB

Pay with—

Available Balance0.00

PD

Mkt Cap

$81.9M

Volume

6.71M

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?PDS Biotechnology has been upgraded to a Zacks Rank #2 (Buy) rating due to rising earnings estimates over the past three months, which increased by 10.6%. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation driven by improved earnings outlook.Zacks Investment Research · Oct 14, 2026

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape CareThe HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.GlobeNewswire Inc. · Sep 30, 2026

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightThe head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.GlobeNewswire Inc. · Jul 21, 2026

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightThe head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.GlobeNewswire Inc. · Jul 13, 2026

Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026The oncology landscape is experiencing rapid regulatory advancement as precision medicine and genomics expand significantly. Multiple biotech companies are advancing cancer therapies toward accelerated FDA approvals in 2026, with the precision medicine market projected to grow from $138.67 billion in 2026 to $537.17 billion by 2035. Key developments include Oncolytics' pelareorep showing strong response rates in anal cancer, CG Oncology's Phase 3 trial ahead of schedule, Zentalis advancing azenosertib in ovarian cancer, ArriVent initiating a pivotal Phase 3 study for firmonertinib, and PDS Biotechnology gaining FDA alignment on trial endpoints.Benzinga · Jan 12, 2026

PDS Biotechnology Announces up to $11.1 Million Registered Direct OfferingPDS Biotechnology announced a registered direct offering of 5.8 million shares and warrants, expecting to raise $5.3 million upfront with potential additional $5.8 million from warrant exercises. The proceeds will support the VERSATILE-003 Phase 3 clinical trial and other research and development expenses.GlobeNewswire Inc. · Nov 11, 2025

PDSB Loss Improves as Costs DropPDS Biotechnology reported a Q2 2025 net loss of $0.21 per share, beating analyst expectations. The company continues advancing its immunotherapy platforms in oncology and infectious disease, with notable progress in clinical trials for HPV and colorectal cancer treatments.The Motley Fool · Aug 13, 2025

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PDS Biotechnology Corporation announced that it granted 7,000 nonstatutory stock options to an employee as a material inducement to employment. The options have an exercise price of $2.25 and vest over a four-year period.GlobeNewswire Inc. · Dec 6, 2024

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and ChemoradiationPDS Biotech announced positive results from its Phase 2 IMMUNOCERV trial, showing a 36-month overall survival rate of 84.4% in locally advanced cervical cancer patients treated with Versamune® HPV and chemoradiation.GlobeNewswire Inc. · Oct 2, 2024

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024PDS Biotechnology will present updated data from the VERSATILE-002 trial evaluating first-line treatment with Versamune® HPV in combination with KEYTRUDA® in patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma at the upcoming ESMO Congress 2024.GlobeNewswire Inc. · Sep 9, 2024

to start trading

PD

PDSBPDS Biotechnology Corporation Common Stock

PDSB

Pay with—

Available Balance0.00

Your PositionYou don't own any PDSB yet.

Related Tickers

Earnings